Viyash Scientific
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Viyash Scientific's recent management commentary highlights a transformative FY26, driven by successful integration and operational leverage, which are expected to enhance revenue growth and margins. The company is strategically expanding its product pipeline and market presence, particularly in the companion animal segment, while pursuing inorganic growth opportunities. Vista's financial outlook reflects a moderate revenue growth trajectory, supported by improving margins and a stable balance sheet. The anticipated 15% revenue growth rate over the next five years aligns with Vista's expectations of continued long-term growth, despite potential short-term pressures from R&D investments. Industry dynamics, including the expanding demand for contract manufacturing and development services, further bolster Viyash's competitive position. However, challenges such as regulatory complexities and raw material supply constraints remain watchpoints. Over the next 12-24 months, key opportunities include the commercialization of new products and strategic partnerships, while headwinds may arise from geopolitical risks and integration challenges. Overall, Viyash is well-positioned to capitalize on emerging opportunities in the veterinary healthcare market, with a focus on innovation and efficiency
Why We Like This Stock
- Successful integration and operational leverage are expected to enhance revenue growth and margins
- A robust product pipeline and strategic partnerships position Viyash for significant market expansion
- Management's target of 15% revenue growth over the next five years aligns with Vista's long-term growth expectations
Things To Watch Out For
- Regulatory complexities in the US companion animal market pose significant risks
- Potential raw material supply constraints may impact production and margins
- Integration challenges from recent mergers could affect operational efficiency
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,370 | 1,551 | 3,420 | 3,730 | 4,090 |
| Profit Before Tax (Cr.) | -43 | 43 | 393 | 611 | 639 |
| PBT Margin | -3.2% | 2.8% | 1149.1% | 16.4% | 15.6% |
| Net Profit (Cr.) | -60 | -47 | 314 | 498 | 443 |
| Earnings Per Share | -1.5 | -1.3 | 6.1 | 9.7 | 10.1 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Anand Rathi | ▲ Buy | 310 | 30-Jun-2026 |
| Systematix Shares | ▲ Buy | 264 | 07-May-2026 |
Company Overview
Show Company Profile
Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services. The company was formerly known as Sequent Scientific Limited and changed its name to Viyash Scientific Limited in January 2026. The company was incorporated in 1985 and is headquartered in Hyderabad, India. Viyash Scientific Limited operates as a subsidiary of CA Harbor Investments.